NO20082101L - Pyrido-, pyrazo- og pyrimido-pyrimidinderivater som mTor inhibitorer - Google Patents

Pyrido-, pyrazo- og pyrimido-pyrimidinderivater som mTor inhibitorer

Info

Publication number
NO20082101L
NO20082101L NO20082101A NO20082101A NO20082101L NO 20082101 L NO20082101 L NO 20082101L NO 20082101 A NO20082101 A NO 20082101A NO 20082101 A NO20082101 A NO 20082101A NO 20082101 L NO20082101 L NO 20082101L
Authority
NO
Norway
Prior art keywords
optionally substituted
group
alkyl group
rog
rer
Prior art date
Application number
NO20082101A
Other languages
English (en)
Other versions
NO341055B1 (no
Inventor
Graeme Caameron Murray Smith
Marc Geoffrey Hummersone
Sylvie Gomez
Keith Allan Menear
Karine Malagu
Heather Mary Ellen Duggan
Xiao-Ling Fan Cockcroft
Gesine Johanna Hermann
Original Assignee
Kudos Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37533284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20082101(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0524047A external-priority patent/GB0524047D0/en
Application filed by Kudos Pharm Ltd filed Critical Kudos Pharm Ltd
Publication of NO20082101L publication Critical patent/NO20082101L/no
Publication of NO341055B1 publication Critical patent/NO341055B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Det tilveiebringes en forbindelse med formel I: hvor: én eller to av X, Xog Xer N og den andre er CH; Rer valgt fra halogen, OR, SR, NRR, NRC(=0)R, NRS0R, en eventuelt substituert C.o heteroarylgruppe eller en eventuelt substituert C.o arylgruppe, hvor Rog Rer valgt fra H, en eventuelt substituert C.arylgruppe, en eventuelt substituert C.heteroarylgruppe eller en eventuelt substituert Ci .7 alkylgruppe;og Rer uavhengig valgt fra H, en eventuelt substituert C.alkylgruppe, en eventuelt substituert C5.20 heteroarylgruppe, en eventuelt substituert C.arylgruppe ellerog Rsammen med nitrogenet hvortil de er bundet danner en heterocyklisk ring inneholdende mellom 3 og 8 ringatomer; Rer valgt fra H, en eventuelt substituert C.arylgruppe, en eventuelt substituert C.heteroarylgruppe, en eventuelt substituert C.alkylgruppe eller NR, hvorog Rer uavhengig valgt fra H, en eventuelt substituert C.alkylgruppe, en eventuelt substituert C5.20 heteroarylgruppe, en eventuelt substituert C.arylgruppe eller Rog Rsammen med nitrogenet hvor til de er bundet danner en heterocyklisk ring inneholdende mellom 3 og 8 ringatomer; Rer valgt fra H, en eventuelt substituert C.arylgruppe, en eventuelt substituert C5.20 heteroarylgruppe eller en eventuelt substituert Ci.alkylgruppe; Rog Rer valgt fra H og en C-alkylgruppe;og R, sammen med nitrogenet hvor til de er bundet, danner en heterocyklisk ring inneholdende mellom 3 og 8 ringatomer; Rer valgt fra H, halogen, OR, SR, NRR, en eventuelt substituert C5.20 heteroarylgruppe og en eventuelt substituert C.arylgruppe, hvor Rog Rer valgt fra H, en eventuelt substituert C.arylgruppe, en eventuelt substituert C.heteroarylgruppe eller en eventuelt substituert C.alkylgruppe;; Rog R6 er uavhengig valgt fra H, en eventuelt substituert C.alkylgruppe, en eventuelt substituert C.heteroarylgruppe og en eventuelt substituert C.arylgruppe ellerog Rsammen med nitrogenet hvortil de er bundet danner en heterocyklisk ring inneholdende mellom 3 og 8 ringatomer eller et farmasøytisk akseptabelt salt derav, med det forbehold at når Rer usubstituert morfolino, Rog Rsammen med nitrogenatomet som de er bundet til danner en usubstituert morfolino og Rer usubstituert fenyl og Xer CH, da er Xikke N og Xer ikke CH eller Xer ikke CH og Xer ikke N og nårer usubstituert piperidinyl, Rra og Rsammen med nitrogenatomet som de er bundet til danner en usubstituert piperidinyl og Rer usubstituert fenyl og Xer CH, da er Xikke CH og Xer ikke N. Det er også gitt fremgangsmåter for fremstilling av en forbindelse med formelen 1 og anvendelse av en forbindelse med formelen 1 som et medikament og ved behandling av kreft.
NO20082101A 2005-11-22 2008-05-06 Pyridopyrimidinforbindelser og anvendelse derav,samt farmasøytisk preparat. NO341055B1 (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US73890205P 2005-11-22 2005-11-22
GB0524047A GB0524047D0 (en) 2005-11-25 2005-11-25 Compounds
US82330906P 2006-08-23 2006-08-23
US82330806P 2006-08-23 2006-08-23
PCT/GB2006/004327 WO2007060404A1 (en) 2005-11-22 2006-11-20 PYRIDO-,PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS

Publications (2)

Publication Number Publication Date
NO20082101L true NO20082101L (no) 2008-08-15
NO341055B1 NO341055B1 (no) 2017-08-14

Family

ID=37533284

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082101A NO341055B1 (no) 2005-11-22 2008-05-06 Pyridopyrimidinforbindelser og anvendelse derav,samt farmasøytisk preparat.

Country Status (15)

Country Link
US (1) US20080194546A1 (no)
EP (1) EP1954699B1 (no)
JP (1) JP5161102B2 (no)
KR (1) KR101464384B1 (no)
AR (1) AR057626A1 (no)
AU (1) AU2006318948B2 (no)
CA (1) CA2628920C (no)
EC (1) ECSP088536A (no)
HR (1) HRP20120963T1 (no)
IL (1) IL191196A (no)
NO (1) NO341055B1 (no)
PL (1) PL1954699T3 (no)
TW (1) TWI452047B (no)
UY (1) UY29938A1 (no)
WO (1) WO2007060404A1 (no)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007081517A2 (en) 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
ATE541844T1 (de) * 2005-12-21 2012-02-15 Abbott Lab Antivirale verbindungen
CN101558067B (zh) * 2006-08-23 2014-05-28 库多斯药物有限公司 作为mtor抑制剂的2-甲基吗啉吡啶并、吡唑并和嘧啶并-嘧啶衍生物
JP5227321B2 (ja) 2006-08-23 2013-07-03 クドス ファーマシューティカルズ リミテッド Ｍｔｏｒ阻害剤としての２−メチルモルホリンピリド−、ピラゾ−及びピリミド−ピリミジン誘導体
EP2094276A4 (en) 2006-12-20 2011-01-05 Abbott Lab ANTIVIRAL COMPOUNDS
JP2010539239A (ja) * 2007-09-17 2010-12-16 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害剤としてのピリドピリミジン誘導体
BRPI0818426A2 (pt) * 2007-10-15 2017-06-13 Astrazeneca Ab produto de combinação, uso de um produto de combinação, e, método para tratar câncer
US8466151B2 (en) 2007-12-26 2013-06-18 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
WO2009104019A1 (en) * 2008-02-21 2009-08-27 Astrazeneca Ab Combination therapy 238
WO2009153597A2 (en) * 2008-06-20 2009-12-23 Astrazeneca Ab Composition and process - 356
EP3023426A1 (en) 2008-07-17 2016-05-25 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
US8163763B2 (en) * 2008-07-31 2012-04-24 Genentech, Inc. Pyrimidine compounds, compositions and methods of use
CA2736361C (en) * 2008-10-31 2017-10-10 Novartis Ag Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
JP2013511526A (ja) 2009-11-18 2013-04-04 ノバルティス アーゲー 固形腫瘍及びその他の悪性腫瘍を治療するための方法及び組成物
WO2011067348A2 (en) 2009-12-03 2011-06-09 Novartis Ag Mek inhibitor salts and solvates thereof
WO2011067356A2 (en) 2009-12-03 2011-06-09 Novartis Ag Polymorphs of a mek inhibitor
BR112012019459A2 (pt) 2010-02-03 2017-10-17 Signal Pharm Llc identificação de mutação de lkb1 como um biomarcador preditivo para sensibilidade para inibidores de tor quinase.
MX2012009059A (es) * 2010-02-22 2012-09-07 Hoffmann La Roche Compuestos inhibidores de fosfoinositida 3-cinasa delta (pi3k) pirido [3,2-d]pirimidina y metodos de uso.
CA2795456A1 (en) 2010-03-30 2011-10-06 Novartis Ag Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling
WO2011120153A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
US20130035336A1 (en) 2010-04-13 2013-02-07 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor for treating cancer
BR112012032884A2 (pt) 2010-06-25 2016-11-08 Novartis Ag compostos e composições heteroarílicos como inibidores de quinase proteica
WO2012099581A1 (en) 2011-01-19 2012-07-26 Takeda Pharmaceutical Company Limited Dihydrofuropyrimidine compounds
CA2843887A1 (en) 2011-08-03 2013-02-07 Signal Pharmaceuticals, Llc Identification of gene expression profile as a predictive biomarker for lkb1 status
CN102911172A (zh) * 2011-08-04 2013-02-06 上海恒瑞医药有限公司 杂芳基并嘧啶类衍生物、其制备方法和用途
CN103374021B (zh) * 2012-04-21 2015-10-28 通化济达医药有限公司 含有锌结合基的吡啶并嘧啶类HDAC和mTOR抑制剂
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
EA033655B1 (ru) 2012-11-29 2019-11-13 Merck Patent Gmbh Производные азахиназолин карбоксамида
WO2014172425A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
JP6382946B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー ジヒドロピラジノ−ピラジンによる癌治療
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
CA2908742C (en) 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
HK1221168A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用於治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的组合疗法
MY189663A (en) 2013-04-17 2022-02-23 Signal Pharm Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
EP3549940A1 (en) 2013-04-17 2019-10-09 Signal Pharmaceuticals, LLC Pharmaceutical formulations, of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
CN107474051B (zh) 2013-05-29 2020-10-30 西格诺药品有限公司 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
TWI656121B (zh) * 2014-08-04 2019-04-11 德商拜耳製藥公司 ２－（嗎啉－４－基）－１，７－萘啶
CN106008559B (zh) * 2015-03-25 2020-10-16 中国科学院上海药物研究所 取代吡啶并嘧啶类化合物的合成工艺
WO2018144791A1 (en) * 2017-02-03 2018-08-09 Millennium Pharmaceuticals, Inc. Combination of vps34 inhibitors and mtor inhibitors
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection
EP3712157A4 (en) * 2017-11-06 2021-04-28 Medshine Discovery Inc. PYRIDOPYRIMIDINE COMPOUNDS AS MTORC 1/2 DOUBLE KINASE INHIBITORS
WO2021133509A1 (en) * 2019-12-27 2021-07-01 Angex Pharmaceutical, Inc. Heterocyclic compounds as mtor inhibitors
US12486274B2 (en) 2020-01-13 2025-12-02 Verge Analytics, Inc. Substituted pyrazolo-pyrimidines and uses thereof
WO2021247859A1 (en) * 2020-06-03 2021-12-09 Yumanity Therapeutics, Inc. Pyridopyrimidines and methods of their use
EP4204412A4 (en) * 2020-08-26 2024-10-09 InventisBio Co., Ltd. HETEROARYL COMPOUNDS, PRODUCTION PROCESSES AND USES THEREOF
CN117088898B (zh) * 2022-05-13 2026-02-06 中国药科大学 稠环嘧啶类化合物及其制备方法、药物组合物和应用
WO2024014885A1 (ko) * 2022-07-13 2024-01-18 일동제약(주) 신규 바이사이클릭 헤테로아릴 화합물 및 이의 용도
WO2024057013A1 (en) * 2022-09-12 2024-03-21 Exscientia Ai Limited Nlrp3 modulators
GB202415232D0 (en) 2024-10-16 2024-11-27 Nacamed As Composition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2940972A (en) * 1957-06-27 1960-06-14 Thomae Gmbh Dr K Tri-and tetra-substituted pteridine derivatives
US4560685A (en) * 1984-06-18 1985-12-24 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung 2-Piperazino-pteridines useful as antithrombotics and antimetastatics
DE3445298A1 (de) * 1984-12-12 1986-06-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue pteridine, verfahren zu ihrer herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
CN1272324C (zh) * 1999-09-07 2006-08-30 辛根塔参与股份公司 新颖的除草剂
AU5261001A (en) * 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd Condensed heteroaryl derivatives
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
GB0428475D0 (en) * 2004-12-30 2005-02-02 4 Aza Bioscience Nv Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders

Also Published As

Publication number Publication date
HK1124039A1 (en) 2009-07-03
CA2628920A1 (en) 2007-05-31
KR101464384B1 (ko) 2014-11-21
AR057626A1 (es) 2007-12-05
HRP20120963T1 (hr) 2012-12-31
AU2006318948A1 (en) 2007-05-31
ECSP088536A (es) 2008-07-30
PL1954699T3 (pl) 2013-01-31
EP1954699A1 (en) 2008-08-13
UY29938A1 (es) 2007-06-29
JP5161102B2 (ja) 2013-03-13
TW200738706A (en) 2007-10-16
US20080194546A1 (en) 2008-08-14
AU2006318948B2 (en) 2011-02-24
NO341055B1 (no) 2017-08-14
CA2628920C (en) 2015-12-29
IL191196A (en) 2016-02-29
KR20080070079A (ko) 2008-07-29
WO2007060404A1 (en) 2007-05-31
JP2009516727A (ja) 2009-04-23
EP1954699B1 (en) 2012-09-19
TWI452047B (zh) 2014-09-11

Similar Documents

Publication Publication Date Title
CY1118879T1 (el) Ενωσεις τριαζινης ως αναστολεις κινασης ρ13 και mtor
MX2021009763A (es) Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos.
DK1261602T3 (da) Imidazol-2-carboxamidderivater som Raf-kinaseinhibitorer
NO20060664L (no) N-substituerte benzimidazolyl C-kit inhibitorer
NO20090443L (no) 2-metylmorfolin pyrido-, pyrazo- and pyrimido-pyrimidin derivater
ATE556058T1 (de) 1-(2h)-isochinolonderivat
HUP0400246A2 (hu) 1,2,4-Trioxolánt tartalmazó maláriaellenes gyógyszerkészítmények és eljárás az előállításukra és az alkalmazásukra
NO20060665L (no) N-substituerte pyrazolyl-amidyl-benzimidazolyl C-kit inhibitorer
NO20060670L (no) N3-substituerte imidazopyridin C-kit inhibitorer
GEP20156282B (en) Compounds and compositions as protein kinase inhibitors
YU18502A (sh) Pteridinoni kao inhibitori kinaza
EA200602060A1 (ru) Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
EA200970461A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
EA200600892A1 (ru) Новые хинолиновые производные
NO20082730L (no) Morfolinopyrimidinderivater og deres anvendelse i terapi
TW200738706A (en) Pyrido-, pyrazo-and pyrimido-pyrimidine derivatives and their use as mTOR inhibitors
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
NO20072689L (no) Tetrasykliske indolderivater som antivirale midler
SE0400284D0 (sv) Novel compounds
WO2007044724A3 (en) Aminopyrimidine, aminopyridine and aniline derivatives inhibitors of pim-i and/or pim-3
EA200701991A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ИМИДАЗО [1,5-a]ПИРИДИНОВ, СПОСОБ ИХ ПОЛУЧЕНИЯ И СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
NO20075409L (no) Substituerte aminoalkyl- og amidoalkyl-benzopyranderivater
NO20052991L (no) Kinazolinforbindelser.
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
NO20080033L (no) Kinolinderivater som NK3-antagonister

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees